Novartis AG ADR (NVS)vsPACS Group, Inc. (PACS)
NVS
Novartis AG ADR
$148.38
-0.14%
HEALTHCARE · Cap: $289.19B
PACS
PACS Group, Inc.
$37.77
-1.23%
HEALTHCARE · Cap: $5.74B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 942% more annual revenue ($56.58B vs $5.43B). NVS leads profitability with a 23.9% profit margin vs 4.5%. PACS appears more attractively valued with a PEG of 1.07. PACS earns a higher WallStSmart Score of 60/100 (C+).
NVS
Hold49
out of 100
Grade: D+
PACS
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.6%
Fair Value
$91.58
Current Price
$148.38
$56.80 premium
Intrinsic value data unavailable for PACS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Earnings expanding 194.1% YoY
Every $100 of equity generates 24 in profit
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
4.5% margin — thin
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PACS
The strongest argument for PACS centers on EPS Growth, Return on Equity. Revenue growth of 11.2% demonstrates continued momentum. PEG of 1.07 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : PACS
The primary concerns for PACS are Profit Margin, Altman Z-Score, Debt/Equity. Debt-to-equity of 3.38 is elevated, increasing financial risk. Thin 4.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a declining stock while PACS is a value play — different risk/reward profiles.
PACS is growing revenue faster at 11.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PACS scores higher overall (60/100 vs 49/100) and 11.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →PACS Group, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
PACS Group, Inc. is a leading technology solutions provider focused on enhancing operational efficiency through a suite of innovative software and hardware systems tailored for diverse industries. The company places a strong emphasis on research and development, positioning itself to capitalize on emerging technological trends and drive digital transformation initiatives. With a strong portfolio of strategic partnerships and a solid market presence, PACS Group is strategically poised to sustain and enhance its competitive advantage, presenting a compelling investment opportunity for institutional investors looking to tap into growth within the dynamic technology sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?